Netherlands-based Royal DSM has for several years been doing smaller deals to beef up its pharma contract development and manufacturing business. So has Canada-based Patheon ($PTI). Now, the two operations will join in a deal valued at $2.6 billion that they say will make them a major force in the pharma services business. Report